Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®) in a patient with graft-versus-host disease

被引：0
|
作者：
Kuhnowski F. [1 ]
Terriou L. [1 ]
Magro L. [1 ]
Jouet J.-P. [1 ]
Yakoub-Agha I. [1 ]
机构：
[1] Service des Maladies du Sang, UAM Allogreffes de CSH, CHRU, Lille
来源：
Drugs | 2006年 / 66卷 / Suppl 2期
关键词：
Imatinib; Tacrolimus; Chronic Myeloid Leukaemia; Mycophenolate Mofetil; Busulfan;
D O I：
10.2165/00003495-200666002-00009
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：29 / 31
页数：2
相关论文
共 50 条
  • [11] Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium After Simultaneous Pancreas-Kidney Transplantation
    Rangel, E. B.
    Melaragno, C. S.
    Sa, J. R.
    Gonzalez, A. M.
    Linhares, M. M.
    Salzedas, A.
    Medina-Pestana, J. O.
    TRANSPLANTATION PROCEEDINGS, 2009, 41 (10) : 4265 - 4269
  • [12] Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients
    Boehler, Torsten
    Canivet, Cindy
    Galvani, Sylvain
    Therville, Nicole
    Salvayre, Robert
    Negre-Salvayre, Anne
    Durand, Dominique
    Thomsen, Mogens
    Rostaing, Lionel
    Kamar, Nassim
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2008, 8 (05) : 769 - 773
  • [13] Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus
    Doukaki, Spyridoula
    Platamone, Andrea
    Alaimo, Roberta
    Bongiorno, Maria Rita
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (01) : 67 - 72
  • [14] Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil
    Arns, W
    Breuer, S
    Choudhury, S
    Taccard, G
    Lee, J
    Binder, V
    Roettele, J
    Schmouder, R
    CLINICAL TRANSPLANTATION, 2005, 19 (02) : 199 - 206
  • [15] Enteric-Coated Mycophenolate SodiumTolerability Profile Compared with Mycophenolate Mofetil
    Matthias Behrend
    Felix Braun
    Drugs, 2005, 65 : 1037 - 1050
  • [16] Enteric-coated Mycophenolate Sodium (myfortic®): An Overview of Current and Future Use in Transplantation
    Bruce Kaplan
    Drugs, 2006, 66 (Suppl 2) : 1 - 8
  • [17] Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children
    Pape, Lars
    Ahlenstiel, Thurid
    Kreuzer, Martin
    Ehrich, Jochen H. H.
    PEDIATRIC TRANSPLANTATION, 2008, 12 (06) : 640 - 642
  • [18] Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus
    Djabarouti, Sarah
    Duffau, Pierre
    Lazaro, Estibaliz
    Chapouly, Candice
    Greib, Carine
    Viallard, Jean-Francois
    Pellegrin, Jean-Luc
    Saux, Marie-Claude
    Breilh, Dominique
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (05) : 689 - 699
  • [19] Bioavailability of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium Is Differentially Affected by Pantoprazole in Healthy Volunteers
    Rupprecht, Korbinian
    Schmidt, Christoph
    Raspe, Anne
    Schweda, Frank
    Shipkova, Maria
    Fischer, Wolfgang
    Bucher, Michael
    Kees, Frieder
    Faerber, Lothar
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (10) : 1196 - 1201
  • [20] Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats
    Jia, Yichen
    Wang, Rulin
    Li, Long
    Zhang, Ying
    Li, Jiawei
    Wang, Jina
    Wang, Xuanchuan
    Qi, Guisheng
    Rong, Ruiming
    Xu, Ming
    Zhu, Tongyu
    BMC PHARMACOLOGY & TOXICOLOGY, 2018, 19
12345